KYMR — Kymera Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1815442 ·
Last close
$121.52
Market Cap
$10.37B
52W High
$142.92
52W Low
$62.91
ADV30
958,848
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -147,232,000 -131,999,000 1,767,269,000 373,374,000 152,742,000
Jun 2026 65,000,000 — -75,607,000 -61,211,000 1,645,444,000 124,477,000 136,188,000
Mar 2026 34,365,000 — -84,154,000 -69,234,000 1,669,016,000 144,090,000 129,379,000
Dec 2025 2,870,000 — -97,896,000 -86,981,000 1,742,812,000 357,011,000 163,148,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-287,565,000
Investing CF
$-415,562,000
Financing CF
$963,973,000
CapEx
$-1,328,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.62
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,328,405,000
Inventory
—
Receivables
$20,000,000
ST Investments
$597,840,000
EBIT TTM
$-349,131,000
Pretax Income TTM
$-349,425,000
Interest Exp TTM
$294,000
Analysts
23

Yahoo Snapshot (yfinance, live)

Total Revenue
$102,235,000
EBITDA
$-398,483,008
Free Cash Flow
$-164,682,000
Enterprise Value
$9,915,965,440
Total Cash
$971,214,016
Total Debt
$76,599,000
Shares Out
85,371,397
Trailing EPS
$-3.64
Book Value
$18.92
ROE
-27.3%
ROA
-17.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 39,211,000 -345,544,000 -311,351,000 1,742,812,000 163,148,000 1,579,664,000 -232,891,000
Dec 2024 47,072,000 -256,710,000 -223,858,000 978,035,000 142,416,000 835,619,000 -194,501,000
Dec 2023 78,592,000 -165,530,000 -146,962,000 575,759,000 180,788,000 394,971,000 -102,826,000
Dec 2022 46,826,000 -161,256,000 -154,808,000 603,134,000 112,983,000 490,151,000 -153,085,000

TTM Snapshot

Revenues TTM
$105,000,000
NetIncome TTM
$-299,601,000
OpCashFlow TTM
—
Assets (Latest)
$1,645,444,000
Forward EPS
$-5.04

Max Pain — expiry 2026-12-18

max pain strike: $110.00 · spot: $121.13 · call oi: 5,798 · put oi: 3,106
Expected Move to 2026-12-18: ±$59.65 (49.24%) — implied range $61.48 – $180.78 · ATM straddle on $120.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RGEN REPLIGEN CORP $10.30B $162.18 —
QGEN QIAGEN N.V. $10.27B $49.75 —
HALO HALOZYME THERAPEUTICS, INC. $10.94B $95.97 —
TECH BIO-TECHNE Corp $11.41B $72.63 —
PCVX Vaxcyte, Inc. $9.40B $59.40 —

News headlines (Yahoo Finance, 1h cache)

Kymera Therapeutics (KYMR) Stock May Be Overvalued Following Positive KT 579 Data
2026-11-05 12:18 · Yahoo
Kymera Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-10-29 22:53 · Yahoo
Kymera (KYMR) Q3 2026 Earnings Call Transcript
2026-10-29 20:44 · Yahoo
Kymera Therapeutics Q3 Earnings Call Highlights
2026-10-29 18:14 · Yahoo
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
2026-10-28 20:01 · Yahoo
Kymera Therapeutics (KYMR) Nears Earnings With KT 621 In Focus, Is The Stock Still Cheap?
2026-10-27 22:16 · Yahoo
Could You Have Seen The Run In Kymera Stock Coming?
2026-10-26 21:34 · Yahoo
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
2026-10-22 20:01 · Yahoo
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
2026-10-19 13:08 · Yahoo
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.